Recent Advancement of the Molecular Diagnosis in Pediatric Brain Tumor

Bae, Jonghee; Won, Jae Kyung; Park, Sung Sup

doi:10.3340/jkns.2018.0057

Cited by 3 publications

(2 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This knowledge is essential for developing personalized treatment strategies and improving patient outcomes. The inclusion of molecular markers has in fact improved diagnostic accuracy and allowed the development of targeted therapies based on genetic anomalies of specific tumor types [137]. Therapies for CNS tumors may include surgery, radiation therapy, chemotherapy, targeted therapies, and immunotherapy in a multidisciplinary approach [138,139].…”

Section: Central Nervous System Tumoursmentioning

confidence: 99%

Biological Implications and Functional Significance of Transglutaminase Type 2 in Nervous System Tumors

Buccarelli,

Castellani,

Fiorentino

et al. 2024

Cells

View full text Add to dashboard Cite

Transglutaminase type 2 (TG2) is the most ubiquitously expressed member of the transglutaminase family. TG2 catalyzes the transamidation reaction leading to several protein post-translational modifications and it is also implicated in signal transduction thanks to its GTP binding/hydrolyzing activity. In the nervous system, TG2 regulates multiple physiological processes, such as development, neuronal cell death and differentiation, and synaptic plasticity. Given its different enzymatic activities, aberrant expression or activity of TG2 can contribute to tumorigenesis, including in peripheral and central nervous system tumors. Indeed, TG2 dysregulation has been reported in meningiomas, medulloblastomas, neuroblastomas, glioblastomas, and other adult-type diffuse gliomas. The aim of this review is to provide an overview of the biological and functional relevance of TG2 in the pathogenesis of nervous system tumors, highlighting its involvement in survival, tumor inflammation, differentiation, and in the resistance to standard therapies.

show abstract

Section: Central Nervous System Tumoursmentioning

confidence: 99%

Biological Implications and Functional Significance of Transglutaminase Type 2 in Nervous System Tumors

Buccarelli,

Castellani,

Fiorentino

et al. 2024

Cells

View full text Add to dashboard Cite

show abstract

“…Pharmacological high-throughput drug screening is readily applied to identify and evaluate potential therapeutics [29]. Moreover, diagnostically, the use of high-throughput omic analysis showed that molecular signatures of pediatric CNS tumors better predict patient outcome compared to histopathology alone [37,38,39,40,41].…”

Section: Applications To the Clinic: The Good The Bad And The Uglymentioning

confidence: 99%

Preclinical Models of Pediatric Brain Tumors—Forging Ahead

Dobson

Gopalakrishnan

2018

Bioengineering

View full text Add to dashboard Cite

Approximately five out of 100,000 children from 0 to 19 years old are diagnosed with a brain tumor. These children are treated with medication designed for adults that are highly toxic to a developing brain. Those that survive are at high risk for a lifetime of limited physical, psychological, and cognitive abilities. Despite much effort, not one drug exists that was designed specifically for pediatric patients. Stagnant government funding and the lack of economic incentives for the pharmaceutical industry greatly limits preclinical research and the development of clinically applicable pediatric brain tumor models. As more data are collected, the recognition of disease sub-groups based on molecular heterogeneity increases the need for designing specific models suitable for predictive drug screening. To overcome these challenges, preclinical approaches will need continual enhancement. In this review, we examine the advantages and shortcomings of in vitro and in vivo preclinical pediatric brain tumor models and explore potential solutions based on past, present, and future strategies for improving their clinical relevancy.

show abstract